Double-blind study of 5-hydroxytryptophan versus placebo in the treatment of primary fibromyalgia syndrome.
A double-blind, placebo-controlled study of the efficacy and tolerability of 5-hydroxytryptophan (5-HTP) was conducted in 50 patients with primary fibromyalgia syndrome. All the clinical parameters studied were significantly improved by treatment with 5-HTP and only mild and transient side-effects were reported. Further controlled studies are required to define properly the value of 5-HTP in patients with primary fibromyalgia syndrome.
Caruso
I
I
Rheumatology Unit, L. Sacco Hospital, Milan, Italy.
Sarzi Puttini
P
P
Cazzola
M
M
Azzolini
V
V
D006916:5-Hydroxytryptophan / Q000627:therapeutic use*; D001007:Anxiety; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005221:Fatigue; D015673:Fatigue Syndrome, Chronic / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010146:Pain; D010919:Placebos; D012890:Sleep
D010919:Placebos; D006916:5-Hydroxytryptophan